Adding more juice to GLP-1s’ recent clinical run, the popular weight loss and diabetes medications have been linked to improvements in addiction-related challenges, according to a study published last week.

Researchers looked at more than 1.3 million health records and found that patients with alcohol and opioid use disorder who were also taking GLP-1 prescriptions had significantly lower rates of intoxication and overdose. Although the drugs are a long way from being approved for addiction, the findings revealed another possible patient group for GLP-1s.

As the patient pool has expanded, so has demand, and brand name GLP-1s from Lilly and Novo Nordisk have been in shortage since 2022, driving a market opportunity for compounding pharmacies. Today we’re looking into the FDA’s decision to take Eli Lilly’s tirzepatide products off the national shortage list and how compounding pharmacies are fighting to keep churning out copycats.

Thanks for reading.